Neutra Corp Achieves Positive Cash Flow in Q1 Following Clinical Research Network Launch

Neutra Life Sciences, a subsidiary of Neutra Corp (OTC: NTRR), has announced a promising start to its operations in the first quarter of 2025, achieving positive operational cash flow within six months of launching. The company, which aims to lead the clinical research industry, has expanded from a single pilot site to a network of four clinical research sites, specializing in areas such as Pediatrics, Pediatric Pulmonology, Family Medicine, Urgent Care, and Optometry. This growth enables Neutra Life Sciences to support complex, late-phase trials across key therapeutic areas.

The company's strategy includes forming joint venture partnerships to expand its research capabilities and infrastructure, focusing on intentional growth and diversified specialties to enhance site performance and patient care. Compared to industry benchmarks, Neutra's rapid establishment of a specialty-rich network in under a year stands out, with plans to add two to three more specialties in the current quarter. Additionally, Neutra Corp is evaluating the potential strategic acquisition of Curaconnector.com, which could complement its operations and increase shareholder value, though the outcome remains uncertain.